More Impact AG: Successful contribution of "The Key" through non-cash capital increase / Market launch of needleless syringe planned

Frankfurt (pta020/06.03.2025/11:10 UTC+1)

More Impact AG: Successful contribution of "The Key" through non-cash capital increase / Market launch of needleless syringe planned

• The Key focuses on the needleless, painless "Speedinject" syringe
• AI-supported and patented technology with applications in human medicine, esthetics and veterinary medicine
• Global market for needle-free drug injection systems is growing by over 9% p.a. until 2032 and is currently worth US$ 7.2 billion
• Market launch of Speedinject targeted for as early as 2025

Frankfurt am Main, March 6, 2025 – More Impact AG (ISIN: DE000A1PG979, "More Impact"), a listed high-tech medical hub, has contributed The Key Unternehmensberatung GmbH ("The Key") as part of a non-cash capital increase. This increases the share capital of More Impact by EUR 87,000,000 to EUR 261,021,434. The non-cash capital increase will be entered in the commercial register of the Frankfurt am Main Local Court in the near future.

More Impact's investee, The Key, focuses on the innovative needleless syringe "Speedinject". The technology, which is protected by several internationally granted patents, enables the pain-free administration of medicinal active substances without the use of needles. The first planned applications focus on insulin and vaccine injections, Botox or hyaluronic acid applications as well as the administration of medication in veterinary medicine. With Speedinject, More Impact is positioning itself in the rapidly growing future-proof market for needleless syringes. According to an industry study, the global market for needle-free drug injection systems is estimated to be worth US$ 7.2 billion in 2024. Growth to US$ 13.4 billion is expected by the end of 2032. This corresponds to a compound annual growth rate (CAGR) of 9.4%.

Speedinject's patented injection technology is based on AI-controlled electromagnetic waves that accelerate the liquid active substance evenly and inject it into the tissue at high speed. AI calculates the precise speed and can determine, among other things, how deep the active substance should be delivered into the tissue. In contrast to conventional pressure methods in the field of needleless injections, the uniform acceleration of the injection fluid prevents a change in the molecular structure of the active substance and an associated loss of efficiency. The high exit speed ensures that the skin's pain receptors are not irritated. As a result, the injection procedure remains completely pain-free. The technology also enables precise local administration down to a tenth of a millimeter. Speedinject's AI-supported electronics can, for example, process relevant data from imaging examinations using ultrasound, X-ray and MRI devices or also consider the results of blood glucose measurements. By incorporating this data from external devices, high-precision injection control and exact dosage can be achieved.

Painless insulin administration for diabetes patients

In human medicine, Speedinject can be used to administer insulin for diabetes. More than 537 million people worldwide currently suffer from diabetes and are largely dependent on insulin. The insulin market is forecast to grow from US$ 28.33 billion in 2023 to US$ 41.63 billion in 2033. Needleless administration can prevent the risk of injury when taking insulin at home and improve overall treatment compliance. By using its own AI in conjunction with the measurement of individual blood glucose levels, the exact dosage of insulin can be calculated for each application.

Speedinject is also suitable as an optimal administration form for so-called "slimming injections".

Speedinject ideal for the esthetics sector

The patented product properties of Speedinject also open up pain-free application options in the field of esthetics. This means that precise amounts of Botox or hyaluronic acid can be placed with an accuracy of millimeters without patients feeling anything or having to worry about optical limitations due to puncture wounds after the treatment. As Botox disintegrates chemically under pressure, Speedinject is the only needle-free technology that is suitable for this area of application.

A wide range of applications in veterinary medicine

In addition to human medicine, Speedinject also has a wide range of applications in veterinary medicine. One area of application for Speedinject could be, for example, vaccinations for livestock in stables, which can be carried out much faster, more hygienically, without waste from disposable syringes and without injury to the animal thanks to the needleless procedure. In small animal practices, the needleless syringe can prevent injuries to staff, as the treated animals do not react to the painless treatment with panic and fear, which in turn enables significantly shorter treatment times.

The market launch of Speedinject in the veterinary medicine sector via direct sales to wholesalers in Germany is planned for 2025. Due to simplified approval procedures, market entry in the esthetic sector is being prepared for 2026. For the human medicine sector with a focus on insulin and weight loss injections, the company does not expect the first revenues in the form of license fees until 2027 at the earliest.

Dr. Gerald Schüssel, CEO of More Impact: "Needleless injections are already a major growth market in medical engineering. With Speedinject, we are tapping into new markets and areas of application for pain-free, precise and efficient drug administration in humans and animals. No pain from punctures, fewer undesirable adverse effects, less risk to medical staff from needlestick injuries and improved general treatment compliance all support the product. We will consistently continue to advance our growth strategy in the coming quarters."

About More Impact AG
More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model.

Contact – Investor & Media Relations
edicto GmbH
Axel Mühlhaus / Svenja Liebig
+49 69 90550 5-50
moreimpact@edicto.de

(end)